Product-Related Factors and Immunogenicity of Biotherapeutics

被引:4
|
作者
Krishna, Murli [1 ]
机构
[1] Bristol Myers Squibb Co, Route 206 & Prov Line Rd, Princeton, NJ 08543 USA
关键词
Biotherapeutic; Immunogenicity risk; CQA; Aggregation; Posttranslational modifications; Impurities; Glycosylation; Product risk assessment; THERAPEUTIC PROTEINS; UNWANTED IMMUNOGENICITY; ANTIBODY THERAPEUTICS; ANTIGEN PRESENTATION; MONOCLONAL-ANTIBODY; DENDRITIC CELLS; INTERFERON-BETA; RISK; PREDICTION; IMPACT;
D O I
10.1007/s12247-019-09423-2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose Biologic molecules constitute a major part of the therapeutics portfolio across the pipeline of several biotech and pharmaceutical companies. They have the advantage of being more target-specific, and recent progress in protein engineering has allowed product designs on various platforms that befit the therapeutic indication and allow differentiation from competitor molecules. They are fundamentally large proteins, with complex structural heterogeneity arising from production using recombinant gene technology in cell lines. These biotherapeutics run the risk of being recognized as foreign by the host immune system, eliciting both B and T cell responses. The impact ranges from none to benign infusion reactions to life-threatening anaphylaxis, and with evolving modalities for such molecules in the pipeline, it is critical to understand the interplay of various risk factors that modulate the immune response. During risk assessment and mitigation strategies in drug development, risk factors are broadly classified arising from patient and product-related origins, and this review will focus on the product-related risk factors. Methods A basic primer on immune mechanisms underlying immunogenicity to a biotherapeutic is provided to highlight those aspects that are influenced by product attributes; this is followed by a more focused discussion of relevant and recently published works pertaining to each critical product attribute and the in vitro and in vivo methodologies utilized to assess their risk. Results Some product-related factors have an influence on the product's immunogenicity. This varies with the type of biotherapeutic product, the disease background, and the diversities seen in the subjects. Conclusion This article highlights some of the experimental limitations on risk evaluation of individual product attributes and emphasizes that immunogenicity manifesting as an undesirable clinical outcome results from the cumulative effect of several risk factors.
引用
收藏
页码:219 / 231
页数:13
相关论文
共 50 条
  • [31] Glow Product-Related Injuries Treated at Emergency Departments
    Hogue, Kelly
    Petty, Lizbeth
    Forrester, Mathias B.
    [J]. CLINICAL TOXICOLOGY, 2020, 58 (11) : 1149 - 1150
  • [32] Technological innovation, organizational change, and product-related services
    Avadikyan, Arman
    Lhuillery, Stephane
    Negassi, Syoum
    [J]. MANAGEMENT, 2016, 19 (04): : 277 - 304
  • [33] PRoduct ONTOlogy:: Defining product-related concepts for logistics planning activities
    Gimenez, Diego A.
    Vegetti, Marcela
    Leone, Horacio P.
    Henninga, Gabriela P.
    [J]. COMPUTERS IN INDUSTRY, 2008, 59 (2-3) : 231 - 241
  • [34] The quintessence of immunogenicity reporting for biotherapeutics
    Shankar, Gopi
    Arkin, Steven
    Devanarayan, Viswanath
    Kromminga, Arno
    Quarmby, Valerie
    Richards, Susan
    Subramanyam, Meena
    Swanson, Steven
    [J]. NATURE BIOTECHNOLOGY, 2015, 33 (04) : 334 - 336
  • [35] THE IMPACT OF PRODUCT-RELATED ANNOUNCEMENTS ON CONSUMER PURCHASE INTENTIONS
    BURKE, RR
    CHO, J
    DESARBO, WS
    MAHAJAN, V
    [J]. ADVANCES IN CONSUMER RESEARCH, 1990, 17 : 342 - 350
  • [36] DOES HOUSEWORK PAY - A PRODUCT-RELATED MICROECONOMIC APPROACH
    GOLDSCHMIDTCLERMONT, L
    [J]. SIGNS, 1983, 9 (01): : 108 - 119
  • [37] Navigating natural product-related patents in Australia and beyond
    Gregg, Claire
    Caine, Michael J.
    [J]. AUSTRALIAN JOURNAL OF CHEMISTRY, 2023, 76 (08) : 413 - 417
  • [38] Protein aggregation and immunogenicity of biotherapeutics
    Pham, Ngoc B.
    Meng, Wilson S.
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2020, 585
  • [39] The quintessence of immunogenicity reporting for biotherapeutics
    Gopi Shankar
    Steven Arkin
    Viswanath Devanarayan
    Arno Kromminga
    Valerie Quarmby
    Susan Richards
    Meena Subramanyam
    Steven Swanson
    [J]. Nature Biotechnology, 2015, 33 : 334 - 336
  • [40] Discovering Relevant Reviews for Answering Product-related Queries
    Zhang, Shiwei
    Lau, Jey Han
    Zhang, Xiuzhen
    Chan, Jeffrey
    Paris, Cecile
    [J]. 2019 19TH IEEE INTERNATIONAL CONFERENCE ON DATA MINING (ICDM 2019), 2019, : 1468 - 1473